Hosted on MSN

Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs

Yesterday afternoon, Neuren Pharmaceuticals Ltd (ASX: NEU) shared feedback from recent US FDA meetings on its NNZ-2591 clinical programs. Neuren said it received constructive guidance for its ...
Yahoo Finance

Neuren Pharmaceuticals’ NNZ-2591 shows promise in trial for Pitt Hopkins syndrome

Australian biopharmaceutical company Neuren Pharmaceuticals has announced positive top-line data from its Phase II trial of NNZ-2591, a treatment for children with Pitt Hopkins syndrome (PTHS). PTHS ...
Motley Fool Australia

Neuren Pharmaceuticals earns FDA Fast Track for NNZ-2591 in PMS

Neuren Pharmaceuticals shares are in focus after the FDA granted Fast Track to its NNZ-2591 treatment for Phelan-McDermid syndrome. Neuren Pharmaceuticals received US FDA Fast Track designation for ...
Kalkine Media

Neuren Pharmaceuticals Secures FDA Orphan Drug Status for NNZ-2591 Targeting Neonatal HIE

FDA awarded Orphan Drug Designation to NNZ-2591 for neonatal hypoxic-ischemic encephalopathy (HIE) treatment; This ...
Business Wire

FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

MELBOURNE, Australia--(BUSINESS WIRE)--Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the ...
RTTNews

FDA Grants Neuren's NNZ-2591 Orphan Drug Designation For Newborn Encephalopathy

Neuren Pharmaceuticals Ltd. (NEU.AX) said Monday the U.S. Food and Drug Administration granted orphan drug designation to NNZ-2591 for neonatal hypoxic-ischemic encephalopathy.
Nasdaq

Neuren’s NNZ-2591 Shows Promise for Pitt Hopkins

Neuren Pharmaceuticals Limited (AU:NEU) has released an update. Neuren Pharmaceuticals Limited has announced promising Phase 2 clinical trial results for NNZ-2591, showing significant improvements in ...
Nasdaq

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ...
BioWorld

Australia’s Neuren raises AU$20M to advance NNZ-2591 to the clinic in three orphan indications

PERTH, Australia – Melbourne-based Neuren Pharmaceuticals Ltd. will be able to progress NNZ-2591 to the clinic for three orphan indications after raising AU$20 million (US$13.75 million) in a ...
Motley Fool Australia

Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. Received written feedback from the US FDA for NNZ-2591 development in both HIE and ...